KPC PharmaceuticalsInc Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	2.8yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

KPC PharmaceuticalsInc no tiene CEO, o no tenemos datos al respecto.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Ting Guo	Director	1.8yrs	sin datos	sin datos
Hui Zhou	Director	less than a year	sin datos	sin datos
Huawei Qiu	Chairman	1.8yrs	sin datos	sin datos
Jin Guo Xin	Independent Director	2.8yrs	CN¥100.00k	sin datos
Ke Liu	Independent Director	5.9yrs	CN¥100.00k	sin datos
Zheng Liang	Director	1.8yrs	sin datos	sin datos
Li Lin Xi	Employee Supervisor	5.9yrs	sin datos	sin datos
Zhang Weng Sen	Employee Supervisor	5.9yrs	sin datos	sin datos
Hongshen Li	Vice Chairman	less than a year	sin datos	sin datos
Zhi Yang	Independent Director	2.8yrs	CN¥100.00k	sin datos
Kang Deng	Supervisor	3.5yrs	sin datos	sin datos

2.8yrs

Permanencia media

52yo

Promedio de edad

Junta con experiencia: La junta directiva de 600422 no se considera experimentada (2.4 años de permanencia promedio), lo que sugiere una nueva junta directiva.

KPC PharmaceuticalsInc Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

KPC Pharmaceuticals,Inc, Annual General Meeting, Jun 21, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

KPC Pharmaceuticals,Inc. to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 20%

New minor risk - Earnings quality

Second quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.12 in 2Q 2023)

Investor sentiment deteriorates as stock falls 16%

Dividend increased to CN¥0.20

KPC Pharmaceuticals,Inc. to Report First Half, 2024 Results on Aug 23, 2024

KPC Pharmaceuticals,Inc, Annual General Meeting, Jun 21, 2024

KPC Pharmaceuticals,Inc to Report Q1, 2024 Results on Apr 27, 2024

Full year 2023 earnings released: EPS: CN¥0.59 (vs CN¥0.51 in FY 2022)

KPC Pharmaceuticals,Inc to Report Fiscal Year 2023 Results on Mar 22, 2024

Third quarter 2023 earnings released

Investor sentiment improves as stock rises 16%

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.14 in 2Q 2022)

Investor sentiment deteriorates as stock falls 16%

Investor sentiment deteriorates as stock falls 16%

KPC Pharmaceuticals,Inc to Report First Half, 2023 Results on Aug 30, 2023

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 15%

Full year 2022 earnings released: EPS: CN¥0.51 (vs CN¥0.67 in FY 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.21 (vs CN¥0.13 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.18 in 2Q 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

First quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.26 in 1Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.17 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.17 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.26 (vs CN¥0.12 in 1Q 2020)

New Hope Healthcare Nanjing Investment Center (Limited Partnership) signed an agreement to acquire 3.7% stake in Nanjing Weili Zhibo Biotechnology Co., Ltd. from KPC Pharmaceuticals, Inc. (SHSE:600422) for CNY 30 million.

Full year 2020 earnings released: EPS CN¥0.60 (vs CN¥0.60 in FY 2019)

New 90-day low: CN¥8.34

KPC Pharmaceuticals, Inc. to Report Fiscal Year 2020 Results on Mar 16, 2021

New 90-day low: CN¥8.38

New 90-day low: CN¥9.12

New 90-day low: CN¥9.54

Third quarter earnings released

KPC Pharmaceuticals, Inc. to Report Q3, 2020 Results on Oct 22, 2020

A group of buyers agreed to acquire 51% stake in Kunming Yinnuo Pharmaceutical Technology Co., Ltd. from KPC Pharmaceuticals, Inc. (SHSE:600422) for approximately CNY 170 million.

KPC Pharmaceuticals, Inc. (SHSE:600422) cancelled the acquisition of 30% stake in Zhejiang Holley Nanhu Pharmaceutical Co., Ltd.

First half earnings released

KPC Pharmaceuticals, Inc. to Report First Half, 2020 Results on Aug 21, 2020

CEO

Miembros de la Junta

Permanencia media

Promedio de edad